A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention

2015610 citationsJournal Article

Authors

Andrew C. Chen · Central Clinical Hospital

Andrew Martin · Royal Prince Alfred Hospital

Bonita Choy · Westmead Hospital

Pablo Fernández‐Peñas · Westmead Hospital

Robyn A. Dalziell

Catriona McKenzie

Richard A. Scolyer · Melanoma Institute Australia

Haryana M. Dhillon

Abstract

Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients. (Funded by the National Health and Medical Research Council; ONTRAC Australian New Zealand Clinical Trials Registry number, ACTRN12612000625875.).

Topics & Keywords

Nonmelanoma Skin Cancer Studies Skin Protection and Aging Cutaneous lymphoproliferative disorders research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 17, pp. 1618-1626

DOI: 10.1056/nejmoa1506197

Field-Weighted Citation Impact: 31.21